6533b825fe1ef96bd1282adb

RESEARCH PRODUCT

A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Federico IngriaNicola GebbiaRoberto ValenzaGiuseppe ZerilloVittorio GebbiaG CannataSalvatore RestivoAntonio Testa

subject

OncologyMaleCancer Researchmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsPilot ProjectsVinorelbineVinblastineVinca alkaloidInternal medicineCarcinomamedicineHumansHead and neckLung cancerMitosisbusiness.industryVinorelbineMiddle Agedmedicine.diseaseVinblastineOncologyHead and Neck NeoplasmsToxicityCarcinoma Squamous CellFemalebusinessmedicine.drug

description

Vinorelbine (VNR), 5′-nor-anhydrovinblastine, is a new semi-synthetic vinka alkaloid with selective affinity for mitotic microtubules, which has been shown to be active against several non small cell lung cancer lines in vitro [1]. VNR has been reported to yield a 34.7 % and 20 % overall response rate in patients with squamous cell lung carcinoma and bronchial adenocarcinoma respectively [2]. Moreover, VNR has been shown to be active in advanced breast carcinoma where it may induce a 30–50 % response rate depending on the extent of pretreatment [3]. We tested the activity and toxicity of single agent VNR given on a weekly schedule in a series of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCHNC).

yearjournalcountryeditionlanguage
1993-01-01European journal of cancer (Oxford, England : 1990)
10.1016/0959-8049(93)90095-whttps://pubmed.ncbi.nlm.nih.gov/8343289